Caidya, a US-based global provider of clinical trial solutions, announced on Monday that it has named Barbara Lopez Kunz as its new chief executive officer, effective 1 September 2024.
In the new role, Kunz is to concentrate on improving the company's position as a global leader in clinical research, emphasising the importance of patient-centred trials and building personalised, fit-for-purpose solutions.
Kunz is a member of the Caidya board of directors. She has a range of experience and has worked in various leadership capacities across the healthcare and life sciences sectors. She has more than 15 years of C-suite experience and a proven track record in driving strategic partnerships and digital transformation. She has held significant P&L responsibilities at major companies including Thermo Fisher Scientific, DuPont, and ICI (now AstraZeneca), as well as at non-profits like Battelle and DIA.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member